TransCode Therapeutics, Inc. (RNAZ)
NASDAQ: RNAZ · Real-Time Price · USD
3.760
-0.060 (-1.57%)
At close: Dec 20, 2024, 4:00 PM
3.830
+0.070 (1.86%)
After-hours: Dec 20, 2024, 7:00 PM EST
TransCode Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
| Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| Selling, General & Admin | 5.23 | 7.15 | 8.4 | 3.4 | 0.44 | 0.23 | |
| Research & Development | 9.43 | 12.26 | 10.23 | 2.75 | 0.28 | 0.23 | |
| Operating Expenses | 14.67 | 19.42 | 18.63 | 6.15 | 0.73 | 0.46 | |
| Operating Income | -14.67 | -19.42 | -18.63 | -6.15 | -0.73 | -0.46 | |
| Interest Expense | -0.04 | -0.06 | -0.03 | -0.1 | -0.39 | -0.16 | |
| Interest & Investment Income | 0 | 0.01 | 0.02 | 0 | 0 | 0 | |
| Other Non Operating Income (Expenses) | 0.07 | 0.92 | 1.08 | -0.59 | -1.22 | 0.01 | |
| EBT Excluding Unusual Items | -14.93 | -18.55 | -17.56 | -6.84 | -2.34 | -0.61 | |
| Gain (Loss) on Sale of Assets | - | - | - | -0 | - | - | |
| Pretax Income | -14.93 | -18.55 | -17.56 | -6.84 | -2.34 | -0.61 | |
| Net Income | -14.93 | -18.55 | -17.56 | -6.84 | -2.34 | -0.61 | |
| Net Income to Common | -14.93 | -18.55 | -17.56 | -6.84 | -2.34 | -0.61 | |
| Free Cash Flow | -15.87 | -18.11 | -15.86 | -5.52 | -0.49 | -0.51 | |
| EBITDA | -14.55 | -19.3 | -18.54 | -6.11 | - | - | |
| D&A For EBITDA | 0.11 | 0.12 | 0.1 | 0.04 | - | - | |
| EBIT | -14.67 | -19.42 | -18.63 | -6.15 | -0.73 | -0.46 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.